Barriers to drug delivery in interventional oncology

Journal of Vascular and Interventional Radiology

Volumn 24, Issue 8, 2013, Pages 1201-1207

  Sheth, Rahul A ^a   Hesketh, Robin ^c   Kong, David S ^b   Wicky, Stephan ^a   Oklu, Rahmi ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; COLLAGENASE; DOXORUBICIN; FREE RADICAL; HYPOXIA INDUCIBLE FACTOR; NANOPARTICLE; PAZOPANIB; SORAFENIB; SUNITINIB; VASCULOTROPIN A; YTTRIUM 90;

ACIDITY; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; APOPTOSIS; ARTIFICIAL EMBOLISM; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL SURVIVAL; CHEMOEMBOLIZATION; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXTRAVASATION; DRUG PENETRATION; DRUG TRANSPORT; EXTRACELLULAR MATRIX; FOOD AND DRUG ADMINISTRATION; GLIOBLASTOMA; HUMAN; HYPOXIA; INTERVENTIONAL RADIOLOGY; KIDNEY CANCER; LAB ON A CHIP; LUNG NON SMALL CELL CANCER; METASTATIC COLORECTAL CANCER; MICROFLUIDICS; MULTIMODALITY CANCER THERAPY; OXYGEN TRANSPORT; PARTICLE SIZE; PH; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; SOLID TUMOR; SUSTAINED RELEASE PREPARATION; THROMBOSIS; TISSUE PRESSURE; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT;

DEB; DRUG-ELUTING BEAD; ECM; EXTRACELLULAR MATRIX; HIF; HYPOXIA-INDUCIBLE FACTOR; IFP; INTERSTITIAL FLUID PRESSURE; RADIOFREQUENCY; RF; VASCULAR ENDOTHELIAL GROWTH FACTOR; VEGF;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CATHETERIZATION; CELL HYPOXIA; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; HUMANS; HYDROGEN-ION CONCENTRATION; MEDICAL ONCOLOGY; NEOPLASMS; PERMEABILITY; RADIOGRAPHY, INTERVENTIONAL; TISSUE DISTRIBUTION; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

EID: 84880712433     PISSN: 10510443     EISSN: 15357732     Source Type: Journal    
DOI: 10.1016/j.jvir.2013.03.034     Document Type: Review

References (43)

1. T.J. Pugh, S.D. Weeraratne, and T.C. Archer Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations Nature 488 2012 106 110
2. L. Chin, W.C. Hahn, G. Getz, and M. Meyerson Making sense of cancer genomic data Genes Dev 25 2011 534 555
3. S. Kobayashi, T.J. Boggon, and T. Dayaram EGFR mutation and resistance of non-small-cell lung cancer to gefitinib N Engl J Med 352 2005 786 792
4. S. Huang, M. Hölzel, and T. Knijnenburg MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling Cell 151 2012 937 950
5. A.I. Minchinton, and I.F. Tannock Drug penetration in solid tumours Nat Rev Cancer 6 2006 583 592
6. J. Folkman Tumor angiogenesis: therapeutic implications N Eng J Med 285 1971 1182 1186
7. H. Hurwitz, L. Fehrenbacher, and W. Novotny Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
8. K. Miller, M. Wang, and J. Gralow Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2007 2666 2676
9. B.I. Rini, S. Halabi, and J.E. Rosenberg Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206 J Clin Oncol 28 2010 2137 2143
10. L.C. Harshman, and S. Srinivas The bevacizumab experience in advanced renal cell carcinoma Onco Targets Ther 3 2010 179 189
11. T. Cloughesy FDA accelerated approval benefits glioblastoma Lancet Oncol 11 2010 1120
12. S. Faivre, G. Demetri, W. Sargent, and E. Raymond Molecular basis for sunitinib efficacy and future clinical development Nat Rev Drug Discov 6 2007 734 745
13. B. Escudier, T. Eisen, and W.M. Stadler Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134
14. A.L. Cheng, Y.K. Kang, and Z. Chen Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 2009 25 34
15. R. Oklu, T.G. Walker, S. Wicky, and R. Hesketh Angiogenesis and current antiangiogenic strategies for the treatment of cancer J Vasc Interv Radiol 21 2010 1791 1805
16. R.K. Jain Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy Nat Med 7 2001 987 989
17. M.R. Mancuso, R. Davis, and S.M. Norberg Rapid vascular regrowth in tumors after reversal of VEGF inhibition J Clin Invest 116 2006 2610 2621
18. W.L. Monsky, J.B. Kruskal, and A.N. Lukyanov Radio-frequency ablation increases intratumoral liposomal doxorubicin accumulation in a rat breast tumor model Radiology 224 2002 823 829
19. A.R. Carson, C.F. McTiernan, and L. Lavery Ultrasound-targeted microbubble destruction to deliver siRNA cancer therapy Cancer Res 72 2012 6191 6199
20. A.A. Manzoor, L.H. Lindner, and C.D. Landon Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors Cancer Res 72 2012 5566 5575
21. S. Singh, A. Sharma, and G.P. Robertson Realizing the clinical potential of cancer nanotechnology by minimizing toxicologic and targeted delivery concerns Cancer Res 72 2012 5663 5668
22. P. Gupta, K. Vermani, and S. Garg Hydrogels: from controlled release to pH-responsive drug delivery Drug Discov Today 7 2002 569 579
23. B.G. De Geest, J.P. Urbanski, T. Thorsen, J. Demeester, and S.C. De Smedt Synthesis of monodisperse biodegradable microgels in microfluidic devices Langmuir 21 2005 10275 10279
24. S. Matsumoto, H. Yasui, J.B. Mitchell, and M.C. Krishna Imaging cycling tumor hypoxia Cancer Res 70 2010 10019 10023
25. J.W. Kim, and C.V. Dang Cancer's molecular sweet tooth and the Warburg effect Cancer Res 66 2006 8927 8930
26. J. von Pawel, R. von Roemeling, U. Gatzemeier, M. Boyer, L.O. Elisson, and P. Clark Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group J Clin Oncol 18 2000 1351 1359
27. O. Trédan, C.M. Galmarini, K. Patel, and I.F. Tannock Drug resistance and the solid tumor microenvironment J Natl Cancer Inst 99 2007 1441 1454
28. R.T. Tong, Y. Boucher, and S.V. Kozin Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors Cancer Res 64 2004 3731 3736
29. F. Winkler, S.V. Kozin, and R.T. Tong Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases Cancer Cell 6 2004 553 563
30. C.A. Znati, M. Rosenstein, and Y. Boucher Effect of radiation on interstitial fluid pressure and oxygenation in a human tumor xenograft Cancer Res 56 1996 964 968
31. M. Leunig, A.E. Goetz, and M. Dellian Interstitial fluid pressure in solid tumors following hyperthermia: possible correlation with therapeutic response Cancer Res 52 1992 487 490
32. K.D. Watson, C.Y. Lai, and S. Qin Ultrasound increases nanoparticle delivery by reducing intratumoral pressure and increasing transport in epithelial and epithelial-mesenchymal transition tumors Cancer Res 72 2012 1485 1493
33. P.A. Netti, L.T. Baxter, Y. Boucher, R. Skalak, and R.K. Jain Time-dependent behavior of interstitial fluid pressure in solid tumors: implications for drug delivery Cancer Res 55 1995 5451 5458
34. R.K. Jain 1995 Whitaker Lecture: delivery of molecules, particles, and cells to solid tumors Ann Biomed Eng 24 1996 457 473
35. L. Eikenes, ∅.S. Bruland, C. Brekken, and C.d.L. Davies Collagenase increases the transcapillary pressure gradient and improves the uptake and distribution of monoclonal antibodies in human osteosarcoma xenografts Cancer Res 64 2004 4768 4773
36. M. Ahmed, and S.N. Goldberg Basic science research in thermal ablation Surg Oncol Clin N Am 20 2011 237 258
37. A. Kennedy, S. Nag, and R. Salem Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium Int J Radiat Oncol Biol Phys 68 2007 13 23
38. R. Salem, K.G. Thurston, B.I. Carr, J.E. Goin, and J.F.H. Geschwind Yttrium-90 microspheres: radiation therapy for unresectable liver cancer J Vasc Interv Radiol 13 suppl 2002 S223 S229
39. J.M. Llovet, M.I. Real, and X. Montañá Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial Lancet 359 2002 1734 1739
40. C.M. Lo, H. Ngan, and W.K. Tso Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma Hepatology 35 2002 1164 1171
41. R.J. Lewandowski, M.F. Mulcahy, and L.M. Kulik Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort Radiology 255 2010 955 965
42. R.J. Lewandowski, J.F. Geschwind, E. Liapi, and R. Salem Transcatheter intraarterial therapies: rationale and overview Radiology 259 2011 641 657
43. X. Wang, C.T. Sofocleous, and J.P. Erinjeri Margin size is an independent predictor of local tumor progression after ablation of colon cancer liver metastases Cardiovasc Intervent Radiol 36 2013 166 175